ROCKWELL MEDICAL INC (RMTI) Stock Fundamental Analysis
USA - NASDAQ:RMTI - US7743743004 - Common Stock
0.87 USD
0 (0%)
Taking everything into account, RMTI scores 3 out of 10 in our fundamental rating. RMTI was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While RMTI seems to be doing ok healthwise, there are quite some concerns on its profitability. RMTI does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
RMTI had negative earnings in the past year.
RMTI had a positive operating cash flow in the past year.
RMTI had negative earnings in each of the past 5 years.
RMTI had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -3.99%, RMTI is in the better half of the industry, outperforming 68.62% of the companies in the same industry.
RMTI has a better Return On Equity (-6.90%) than 68.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.99% | ||
| ROE | -6.9% | ||
| ROIC | N/A |
ROA(3y)-19.01%
ROA(5y)-32.81%
ROE(3y)-57.83%
ROE(5y)-310.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 17.52%, RMTI is not doing good in the industry: 81.91% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of RMTI has grown nicely.
RMTI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 17.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y30.04%
2. Health
2.1 Basic Checks
RMTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
RMTI has more shares outstanding than it did 1 year ago.
RMTI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, RMTI has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -7.79, we must say that RMTI is in the distress zone and has some risk of bankruptcy.
RMTI has a Altman-Z score of -7.79. This is in the lower half of the industry: RMTI underperforms 71.81% of its industry peers.
RMTI has a debt to FCF ratio of 3.93. This is a good value and a sign of high solvency as RMTI would need 3.93 years to pay back of all of its debts.
The Debt to FCF ratio of RMTI (3.93) is better than 80.85% of its industry peers.
A Debt/Equity ratio of 0.33 indicates that RMTI is not too dependend on debt financing.
RMTI has a Debt to Equity ratio of 0.33. This is comparable to the rest of the industry: RMTI outperforms 49.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | 3.93 | ||
| Altman-Z | -7.79 |
ROIC/WACCN/A
WACC8.16%
2.3 Liquidity
A Current Ratio of 2.89 indicates that RMTI has no problem at all paying its short term obligations.
RMTI has a Current ratio of 2.89. This is comparable to the rest of the industry: RMTI outperforms 57.45% of its industry peers.
A Quick Ratio of 2.51 indicates that RMTI has no problem at all paying its short term obligations.
With a decent Quick ratio value of 2.51, RMTI is doing good in the industry, outperforming 61.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.51 |
3. Growth
3.1 Past
RMTI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -213.73%.
The Revenue has grown by 21.38% in the past year. This is a very strong growth!
The Revenue has been growing by 10.61% on average over the past years. This is quite good.
EPS 1Y (TTM)-213.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)21.38%
Revenue growth 3Y17.9%
Revenue growth 5Y10.61%
Sales Q2Q%-43.75%
3.2 Future
RMTI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -89.45% yearly.
Based on estimates for the next years, RMTI will show a decrease in Revenue. The Revenue will decrease by -9.82% on average per year.
EPS Next Y-750%
EPS Next 2Y-151.28%
EPS Next 3Y-89.45%
EPS Next 5YN/A
Revenue Next Year-31.95%
Revenue Next 2Y-13.1%
Revenue Next 3Y-9.82%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
RMTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RMTI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, RMTI is valued a bit cheaper than 78.72% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of RMTI indicates a rather cheap valuation: RMTI is cheaper than 95.21% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.16 | ||
| EV/EBITDA | 17.1 |
4.3 Compensation for Growth
RMTI's earnings are expected to decrease with -89.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-151.28%
EPS Next 3Y-89.45%
5. Dividend
5.1 Amount
RMTI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:RMTI (11/18/2025, 12:11:04 PM)
0.87
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners17.19%
Inst Owner Change-6.54%
Ins Owners4.38%
Ins Owner Change14.41%
Market Cap29.95M
Revenue(TTM)101.49M
Net Income(TTM)-2.10M
Analysts82.5
Price Target3.83 (340.23%)
Short Float %3.53%
Short Ratio1.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.76%
Min EPS beat(2)1.96%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)53.92%
Min EPS beat(4)-198.04%
Max EPS beat(4)390.2%
EPS beat(8)6
Avg EPS beat(8)44.81%
EPS beat(12)9
Avg EPS beat(12)35.07%
EPS beat(16)12
Avg EPS beat(16)34.77%
Revenue beat(2)1
Avg Revenue beat(2)1.34%
Min Revenue beat(2)-3.53%
Max Revenue beat(2)6.2%
Revenue beat(4)3
Avg Revenue beat(4)2.42%
Min Revenue beat(4)-3.53%
Max Revenue beat(4)6.2%
Revenue beat(8)6
Avg Revenue beat(8)2.54%
Revenue beat(12)8
Avg Revenue beat(12)2.49%
Revenue beat(16)9
Avg Revenue beat(16)-0.35%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.18%
EPS NY rev (1m)0%
EPS NY rev (3m)14.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.34 | ||
| P/FCF | 11.16 | ||
| P/OCF | 8.57 | ||
| P/B | 0.99 | ||
| P/tB | 1.53 | ||
| EV/EBITDA | 17.1 |
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)0.08
FCFY8.96%
OCF(TTM)0.1
OCFY11.67%
SpS2.55
BVpS0.88
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.99% | ||
| ROE | -6.9% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 17.52% | ||
| FCFM | 3.05% |
ROA(3y)-19.01%
ROA(5y)-32.81%
ROE(3y)-57.83%
ROE(5y)-310.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y30.04%
F-Score6
Asset Turnover1.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | 3.93 | ||
| Debt/EBITDA | 11.07 | ||
| Cap/Depr | 37.16% | ||
| Cap/Sales | 0.92% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 390.29% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.51 | ||
| Altman-Z | -7.79 |
F-Score6
WACC8.16%
ROIC/WACCN/A
Cap/Depr(3y)323.45%
Cap/Depr(5y)234.89%
Cap/Sales(3y)5.5%
Cap/Sales(5y)3.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-213.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y-750%
EPS Next 2Y-151.28%
EPS Next 3Y-89.45%
EPS Next 5YN/A
Revenue 1Y (TTM)21.38%
Revenue growth 3Y17.9%
Revenue growth 5Y10.61%
Sales Q2Q%-43.75%
Revenue Next Year-31.95%
Revenue Next 2Y-13.1%
Revenue Next 3Y-9.82%
Revenue Next 5YN/A
EBIT growth 1Y58.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-161.54%
EBIT Next 3Y-29.69%
EBIT Next 5YN/A
FCF growth 1Y134.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y147.84%
OCF growth 3YN/A
OCF growth 5YN/A
ROCKWELL MEDICAL INC / RMTI FAQ
What is the ChartMill fundamental rating of ROCKWELL MEDICAL INC (RMTI) stock?
ChartMill assigns a fundamental rating of 3 / 10 to RMTI.
What is the valuation status for RMTI stock?
ChartMill assigns a valuation rating of 2 / 10 to ROCKWELL MEDICAL INC (RMTI). This can be considered as Overvalued.
How profitable is ROCKWELL MEDICAL INC (RMTI) stock?
ROCKWELL MEDICAL INC (RMTI) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for RMTI stock?
The Earnings per Share (EPS) of ROCKWELL MEDICAL INC (RMTI) is expected to decline by -750% in the next year.